MktsMarkets

Rocket Pharmaceuticals, Inc.
NASDAQ: RCKTKey statistics
RCKT News
Stories mentioning RCKT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 31,454 | 29,347 | 34,068 | 42,658 | 35,942 | 37,357 | 42,315 | 46,345 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 48,511 | 43,963 | 52,247 | 71,149 | 64,388 | 62,694 | 69,424 | 73,712 |
| Operating Income (Loss) | (48,511) | (43,963) | (52,247) | (71,149) | (64,388) | (62,694) | (69,424) | (73,712) |
| Interest Income | ||||||||
| Interest Expense | 473.00 | 473.00 | 473.00 | 473.00 | 472.00 | 473.00 | 471.00 | 471.00 |
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (47,594) | (42,538) | (50,332) | (68,919) | (61,334) | (60,327) | (66,719) | (69,646) |
| Earnings Per Share (Basic) | (0.42) | (0.38) | (0.45) | (0.62) | (0.56) | (0.64) | (0.71) | (0.74) |
| Earnings Per Share (Diluted) | (0.42) | (0.38) | (0.45) | (0.62) | (0.56) | (0.64) | (0.71) | (0.74) |
| Weighted Average Shares Outstanding (Basic) | 112,134 | 111,124 | 111,571 | 111,020 | 110,093 | 94,808 | 94,158 | 93,746 |
| Weighted Average Shares Outstanding (Diluted) | 112,134 | 111,124 | 111,571 | 111,020 | 110,093 | 94,808 | 94,158 | 93,746 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About RCKT
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a stock listed on the Nasdaq Stock Market under the ticker symbol RCKT. It last traded at $2.44 (Nov 10, 2026, 9:30 AM ET), down 3.6% on the day. That gives Rocket Pharmaceuticals a market capitalisation of $261.8M.
Over the past 52 weeks RCKT has traded between $2.17 and $5.45.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $47.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | $0 | -$47.6M |
| Dec 31, 2025 | $0 | -$42.5M |
| Sep 30, 2025 | $0 | -$50.3M |
| Jun 30, 2025 | $0 | -$68.9M |
From Rocket Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…